Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
WAIKOLOA, Hawaii — In this Healio Video Perspective from Retina 2026, Roger A. Goldberg, MD, MBA, discusses Encelto for the treatment of macular telangiectasia type 2.
Encelto (revakinagene taroretcel-lwey, Neurotech Pharmaceuticals) was approved for the treatment of macular telangiectasia (MacTel) type 2 in March 2025. Goldberg, of Bay Area Retina Associates, presented findings from a study that explored surgical-related adverse events associated with the implant. He and colleagues reviewed complications from six clinical trials of Encelto.
{{VIDEO}}
“We wanted to look at all of the surgical